Alivus Life Sciences Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2026, recommended Final Dividend of Rs. 5 per equity share.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alivus Life Sciences reported strong full-year results with revenue from operations growing 6.9% to Rs. 25,518 million and profit after tax rising 16.2% to Rs. 5,645 million. The board recommended a final dividend of Rs. 5 per share (250% on Rs. 2 face value), subject to shareholder approval. The auditors issued an unmodified opinion, confirming clean financials. An exceptional item of Rs. 257 million was recorded due to statutory impact of new labour codes (gratuity and compensated absences). Operating cash flow remained healthy at Rs. 5,654 million.
The company delivered solid profit growth and maintained clean audit status, which is positive for investors. The dividend declaration signals confidence in financial health, though the growth rate of ~16% PAT growth is moderate and below the 25% threshold.